Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as GLP-1 receptor agonists, including the popular name brands Ozempic, Wegovy, Mounjaro and Zepbound. As obesity rates rise, eligibility expands and curiosity about these medications grows, more people are exploring their potential benefits.
This article was originally published on MedicalXpress.com